Trial Profile
A study evaluating predictors of loss of response and dose intensification, need for routine therapeutic drug monitoring in inflammatory bowel disease patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacodynamics; Pharmacokinetics
- 12 Dec 2016 New trial record
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week